Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)

被引：0
|
作者：
Quintas-Cardama, A.
Kantarjian, H.
Andreef, M.
Faderl, S.
Wright, J.
Zhang, W.
Konopleva, M.
Verstovsek, S.
Borthakur, G.
Cortes, J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7018
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma.
    Flaherty, KT
    Redlinger, M
    Schuchter, LM
    Lathia, CD
    Weber, BL
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 201S - 201S
  • [22] Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.
    Hirte, H
    Moore, MJ
    Oza, AM
    Siu, LL
    Harris, H
    Maclean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [23] SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas
    El-Khoueiry, A. B.
    Rankin, C.
    Lenz, H. J.
    Philip, P.
    Rivkin, S. E.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A phase II study of BAY 43-9006 (sorafenib) in patients with androgen-independent prostate cancer (AlPC)
    Dahut, W.
    Posadas, E.
    Scripture, C.
    Gulley, J.
    Arlen, P.
    Wright, J.
    Harold, N.
    Fioravanti, S.
    Figg, W.
    EJC SUPPLEMENTS, 2005, 3 (02): : 248 - 248
  • [25] Final analysis of a randomized phase I study of the C-RAF kinase inhibitor BAY 43-9006 in patients with acute myeloid leukemia
    Crump, Michael
    Leber, Brian
    Buckstein, Rena
    Kassis, Jeanine
    Headley, David
    Minden, Mark
    Petrenciuc, Oana
    Maclntosh, Lynn
    Seymour, Leslet
    Eisenhauer, Elizabeth
    ANNALS OF ONCOLOGY, 2004, 15 : 154 - 154
  • [26] A phase I study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer
    Yamada, Yasuhide
    Minami, Hironobu
    Fuse, Nozomu
    Ohtsu, Atsushi
    Kato, Ken
    Kiyota, Naomi
    Shimada, Yasushiro
    Doi, Toshihiko
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Fujiwara, Yutaka
    Ito, Yuichiro
    Mera, Kiyomi
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [27] Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma
    Robert, C.
    Lassau, N.
    Angevin, E.
    Soria, J.
    Chami, L.
    Zarafana, E.
    Landreau, V.
    Schwartz, B.
    Armand, J.
    Escudier, B.
    EJC SUPPLEMENTS, 2005, 3 (02): : 254 - 254
  • [28] Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    Escudier, B.
    Szczylik, C.
    Eisen, T.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Shan, M.
    Bukowski, R. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 226
  • [29] Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma
    Gollob, J. A.
    Moran, K.
    Richmond, T.
    Jones, J. M.
    Baell, T. E.
    Rathmell, W. K.
    Peterson, B. L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 227
  • [30] Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
    Escudier, B
    Szczylik, C
    Eisen, T
    Stadler, WM
    Schwartz, B
    Shan, M
    Bukowski, RM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1093S - 1093S
12345